A Study of [14C]-LY3537982 in Healthy Participants
A Phase I, Open-label, Two-part Study of the Absorption, Metabolism, Excretion, and the Absolute Bioavailability of [14C]-LY3537982 in Healthy Adult Subjects
Sponsor: Eli Lilly and Company + Loxo Oncology, Inc.
No open prediction endpoints
Endpoints are classified and published by ProgramSignal analysts.
Request endpoint coverageKey Facts
Primary Endpoints (CT.gov)
Pharmacokinetics (PK): Fraction of Dose Excreted in Urine (Feur)
Time frame: Predose on day 1 up to postdose on day 21 (Part 1)
PK: Cumulative Feur
Time frame: Predose on day 1 up to postdose on day 21 (Part 1)
PK: Fraction of Dose Excreted in Feces (Fefeces)
Time frame: Predose on day 1 up to postdose on day 21 (Part 1)
PK: Cumulative Fefeces
Time frame: Predose on day 1 up to postdose on day 21 (Part 1)
Eligibility Criteria
Inclusion Criteria: * Male and female participants in good health, determined by no clinically significant findings from medical history, physical examination as assessed by the investigator. * Have a body mass index within the range 18.5 to 32.0 kilograms per meter squared (kg/m²) * Female participants of non-childbearing potential and male participants who follow standard contraceptive methods. Exclusion Criteria: * History or presence of any diseases or conditions of clinical significance by the Investigator (or designee) and/or Sponsor * Known ongoing alcohol and/or drug abuse within 2 years prior to Screening * History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator
✦ Analyst Commentary
Expert commentary on why this trial matters and what to watch for.
Request coverage →